Label-free electrochemical lateral flow device for detection of CReactive protein

Session

Pharmaceutical and Natural Sciences

Description

C-reactive protein (CRP) is synthesized by the liver in response to inflammation and serves as an important biomarker of systemic inflammation. Elevated CRP levels are frequently observed in patients with infections, cardiovascular disorders, malignancies, and metabolic syndromes. Despite its broad clinical significance, CRP detection in current practice still relies heavily on established techniques such as ELISA, immunoturbidimetry, and latex-based methods. Although effective, these approaches often involve multiple operational steps and specialized instrumentation, which limits their applicability in time-sensitive or resource limited contexts. Electrochemical lateral flow immunoassays (eLFIAs) are regarded as an excellent alternative to conventional LFIAs for CRP detection due to their ease of use, rapid response, high sensitivity, and strong selectivity. However, conventional eLFIA methods require labeling materials to generate electrochemical signals, resulting in complex preparation and multi-step detection. To address these limitations, this work focuses on developing a label-free eLFIA (LF-eLFIA) for CRP detection, characterized by simplified preparation and reduced detection steps. The LF-eLFIA strategy integrates these processes into a single operation through the introduction of a polymeric time-delay mechanism that regulates the release of redox species. This enables simultaneous immunocomplex formation and signal generation. Notably, the device is capable of detecting CRP concentrations in the clinically relevant range for cardiovascular risk prediction (3–10 mg/L), with a limit of detection (LOD) as low as 0.1 mg/L. Consequently, the method enhances the practicality of CRP testing and provides a streamlined solution well-suited for decentralized diagnostics.

Keywords:

Electrochemical lateral flow immunoassay, Label-free electrochemical immunoassay, C-reactive protein, Polymeric time-delay

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-982-41-2

Location

UBT Lipjan, Kosovo

Start Date

25-10-2025 9:00 AM

End Date

26-10-2025 6:00 PM

DOI

10.33107/ubt-ic.2025.341

This document is currently not available here.

Share

COinS
 
Oct 25th, 9:00 AM Oct 26th, 6:00 PM

Label-free electrochemical lateral flow device for detection of CReactive protein

UBT Lipjan, Kosovo

C-reactive protein (CRP) is synthesized by the liver in response to inflammation and serves as an important biomarker of systemic inflammation. Elevated CRP levels are frequently observed in patients with infections, cardiovascular disorders, malignancies, and metabolic syndromes. Despite its broad clinical significance, CRP detection in current practice still relies heavily on established techniques such as ELISA, immunoturbidimetry, and latex-based methods. Although effective, these approaches often involve multiple operational steps and specialized instrumentation, which limits their applicability in time-sensitive or resource limited contexts. Electrochemical lateral flow immunoassays (eLFIAs) are regarded as an excellent alternative to conventional LFIAs for CRP detection due to their ease of use, rapid response, high sensitivity, and strong selectivity. However, conventional eLFIA methods require labeling materials to generate electrochemical signals, resulting in complex preparation and multi-step detection. To address these limitations, this work focuses on developing a label-free eLFIA (LF-eLFIA) for CRP detection, characterized by simplified preparation and reduced detection steps. The LF-eLFIA strategy integrates these processes into a single operation through the introduction of a polymeric time-delay mechanism that regulates the release of redox species. This enables simultaneous immunocomplex formation and signal generation. Notably, the device is capable of detecting CRP concentrations in the clinically relevant range for cardiovascular risk prediction (3–10 mg/L), with a limit of detection (LOD) as low as 0.1 mg/L. Consequently, the method enhances the practicality of CRP testing and provides a streamlined solution well-suited for decentralized diagnostics.